^
Association details:
Biomarker:IDH2 mutation + ALK fusion
Cancer:Non Small Cell Lung Cancer
Drug Class:ALK inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

NGS-based liquid-biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step towards personalized NSCLC treatment

Published date:
05/31/2021
Excerpt:
We collected 26 plasma and two cerebrospinal fluid samples from 24 advanced ALK-positive NSCLC patients at disease progression to an ALK-I...Potential ALK-I-resistance mutations were also found in PIK3CA and IDH2.
DOI:
https://doi.org/10.1002/1878-0261.13033